Structural requirements for uptake and recognition of CpG oligonucleotides

International Journal of Medical Microbiology

Volumn 298, Issue 1-2, 2008, Pages 33-38

  Heeg, Klaus ^a   Dalpke, Alexander ^a   Peter, Mirjam ^a   Zimmermann, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adjuvant; CpG DNA; Dendritic cells; Epigenetic; IL 12

Indexed keywords

BACTERIAL DNA; CPG OLIGODEOXYNUCLEOTIDE; DOUBLE STRANDED DNA; IMMUNOLOGICAL ADJUVANT; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P40; PATTERN RECOGNITION RECEPTOR; SINGLE STRANDED DNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ACETYLATION; ADAPTIVE IMMUNITY; B LYMPHOCYTE ACTIVATION; CELL SUBPOPULATION; CHEMICAL STRUCTURE; DENDRITIC CELL; DNA SEQUENCE; EPIGENETICS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; LEISHMANIA MAJOR; MOLECULAR RECOGNITION; NONHUMAN; NUCLEOSOME; PROMOTER REGION; SHORT SURVEY; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; VACCINATION;

EID: 36749081174     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2007.07.007     Document Type: Short Survey

References (30)

1. Akira S., and Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85 (2003) 85-95
2. Albrecht I., Tapmeier T., Zimmermann S., Frey M., Heeg K., and Dalpke A. Toll-like receptor (TLR) selective nucleosomal remodeling at the IL-12p40 promoter. EMBO Rep 5 (2004) 172-177
3. Barton G.M., Kagan J.C., and Medzhitov R. Intracellular localization of TLR9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 7 (2006) 49-56
4. Bartz H., Mendoza Y., Gebker M., Fischborn T., Heeg K., and Dalpke A. Poly-guanosine strings improve cellular uptake and stimulatory activity of phosphodiester CpG oligonucleotides in human leukocytes. Vaccine 23 (2004) 148-155
5. Bell J.K., Mullen G.E., Leifer C.A., Mazzoni A., Davies D.R., and Segal D.M. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 24 (2003) 528-533
6. Bell J.K., Botos I., Hall P.R., Askins J., Shiloach J., Segal D.M., and Davies D.R. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc. Natl. Acad. Sci. USA 102 (2005) 10976-10980
7. Bell J.K., Askins J., Hall P.R., Davies D.R., and Segal D.M. The dsRNA binding site of human Toll-like receptor 3. Proc. Natl. Acad. Sci. USA 103 (2006) 8792-8797
8. BenMohamed L., Wechsler S.L., and Nesburn A.B. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2 (2002) 425-431
9. Dalpke A., and Heeg K. CpG DNA as immune response modifier. Int. J. Med. Microbiol. 294 (2004) 345-354
10. Dalpke A., Zimmermann S., and Heeg K. CpG oligonucleotides in vaccination: signaling and mechanisms of action. Immunobiology 204 (2001) 667-676
11. Dalpke A., Zimmermann S., Albrecht I., and Heeg K. Phosphodiester CpG oligonucleotides as adjuvants: Poly-guanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 106 (2002) 102-112
12. Dalpke A., Zimmermann S., and Heeg K. CpG-DNA in the prevention and treatment of infections. BioDrugs 16 (2002) 419-431
13. Dalpke A., Zimmermann S., and Heeg K. Immunopharmacology of CpG DNA. Biol. Chem. 383 (2002) 1491-1500
14. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., and Nemazee D. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314 (2006) 1936-1938
15. He G., Patra A., Siegmund K., Peter M., Heeg K., Dalpke A., and Richert C. Immunostimulatory CpG oligonucleotides form defined three-dimensional structures: results from an NMR study. Chem. Med. Chem 2 (2007) 549-560
16. Heeg K., and Zimmermann S. CpG DNA as a Th1 trigger. Int. Arch. Allergy Immunol. 121 (2000) 87-97
17. Kabelitz D., and Medzhitov R. Innate immunity - cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr. Opin. Immunol. 19 (2007) 1-3
18. Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 2 (2003) 305-315
19. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5 (2006) 471-484
20. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., and Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27 (1997) 2340-2344
21. Lipford G.B., Bendigs S., Heeg K., and Wagner H. Poly-guanosine motifs costimulate antigen reactive CD8T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines. Immunology 101 (2000) 46-52
22. Medzhitov R., and Janeway C.A. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9 (1997) 4-9
23. Medzhitov R., and Janeway C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91 (1997) 295-298
24. Narayanan S., Dalpke A.H., Siegmund K., Heeg K., and Richert C. CpG oligonucleotides with modified termini and nicked dumbbell structure show enhanced immunostimulaty activity. J. Med. Chem. 46 (2003) 5031-5044
25. Schild H., Deres K., Wiesmüller K.H., Jung G., and Rammensee H.G. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur. J. Immunol. 21 (1991) 2649-2654
26. Sieling P.A., Chung W., Duong B.T., Godowski P.J., and Modlin R.L. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol. 170 (2003) 194-200
27. Todate A., Suda T., Kuwata H., Chida K., and Nakamura H. Muramyl dipeptide-Lys stimulates the function of human dendritic cells. J. Leukoc. Biol. 70 (2001) 723-729
28. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 25 (2004) 381-386
29. Zimmermann S., Egeter O., Hausmann S., Lipford G.B., Röcken M., Wagner H., and Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160 (1998) 3627-3630
30. Zimmermann S., Dalpke A., and Heeg K. Immunostimulatory DNA as adjuvants: efficacy of phosphodiester CpG oligonucleotides is enhanced by 5′ sequence modifications. Vaccine 21 (2003) 990-995